Category 6 - PATHOLOGY SERVICES
73303 - Additional Information
Item Start Date:
01-Apr-2022
Description Updated:
01-Apr-2022
Schedule Fee Updated:
01-Apr-2022
Group
P7 - Genetics
A test of tumour tissue from a patient with metastatic castration-resistant prostate cancer, including subsequent characterisation of germline gene variants should tumour tissue testing undertaken during the same service be inconclusive, requested by a specialist or consultant physician, to determine eligibility relating to BRCA status for access to olaparib under the Pharmaceutical Benefits Scheme.
Applicable once per primary tumour diagnosis
Fee: $1,000.00 Benefit: 75% = $750.00 85% = $901.30
Legend
- Assist - Addition/Deletion of (Assist.)
- Amend - Amended Description
- Anaes - Anaesthetic Values Amended
- Emsn - EMSN Change
- Fee - Fee Amended
- Renum - Item Number Change (renumbered)
- New - New Item
- NewMin - New Item (previous Ministerial Determination)
- Qfe - QFE Change